Tag: #Global Trends

Key Development A $1.74 billion valuation for a biotech with no commercial product might appear aggressive. But ADARx enters the... Read more

Key Development Johnson & Johnson (J&J) has unveiled pivotal Phase 3 data (Study 451) demonstrating that lumateperone (Caplyta) significantly curtails... Read more

Key Development 11.1 months versus 5.5 months. That was median progression-free survival for Inluriyo plus Verzenio compared with Inluriyo alone... Read more

Key Development Two biotechs filed for IPOs on the same day, yet one held nearly $91 million of cash and... Read more

Key Development Nearly 94% of Novo Nordisk's 2025 revenue came from diabetes and obesity. That concentration explains why investors are... Read more

Key Development A reference market worth an estimated $5.7 billion is being targeted by a biosimilar still in early-stage development.... Read more

Key Development Turning one vaccination encounter into five doses delivered six months apart would change far more than the injection... Read more

Key Development AstraZeneca and Daiichi Sankyo have secured an important access milestone in the UK, with Enhertu (trastuzumab deruxtecan) cleared... Read more

Key Development A multi-institutional research team from Georgia State University, Emory University, and the University of Alabama at Birmingham has... Read more